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Abstract
Introduction: Anti-RNA polymerase III (RNAP III) antibodies are highly specific markers of scleroderma (systemic
sclerosis, SSc) and associated with a rapidly progressing subset of SSc. The clinical presentation of anti-RNAP III
positive patients, onset of Raynaud’s phenomenon (RP) and SSc in unselected patients in a rheumatology clinic
were evaluated.
Methods: Autoantibodies in sera from 1,966 unselected patients (including 434 systemic lupus erythematosus
(SLE), 119 SSc, 85 polymyositis/dermatomyositis (PM/DM)) in a rheumatology clinic were screened by
radioimmunoprecipitation. Anti-RNAP III positive sera were also tested by immunofluorescence antinuclear
antibodies and anti-RNAP III ELISA. Medical records of anti-RNAP III positive patients were reviewed.
Results: Among 21 anti-RNAP III positive patients, 16 met the American College of Rheumatology (ACR) SSc criteria
at the initial visit but 5 did not; diagnoses were vasculitis, early polyarthritis, renal failure with RP, interstitial lung
disease, and Sjögren’s syndrome. The first two patients developed rapidly progressive diffuse SSc. An additional
case presented with diffuse scleroderma without RP and RP developed two years later. Anti-RNAP III antibodies in
these 6 cases of atypical clinical presentation were compared with those in 15 cases of typical (SSc with RP) cases.
Anti-RNAP III levels by ELISA were lower in the former group (P = 0.04 by Mann-Whitney test) and 3 of 6 were
negative versus only 1 of 15 negative in the latter (P < 0.05 by Fisher’s exact test). Three cases of non-SSc anti-
RNAP III positive patients had predominant reactivity with RNAP I with weak RNAP III reactivity and had a strong
nucleolar staining. Three anti-RNAP III patients, who did not have RP at the initial visit, developed RP months later.
Scleroderma developed prior to RP in 5 out of 16 (31%) in the anti-RNAP III group, but this was rare in patients
with other autoantibodies. The interval between the onset of RP to scleroderma was short in anti-RNAP III positive
patients.
Conclusions: Anti-RNAP III antibodies are highly specific for SSc; however, a subset of anti-RNAP III positive
patients do not present as typical SSc. The interval between RP and scleroderma in this group is short, and 31% of
patients developed scleroderma prior to RP in this group. Anti-RNAP III positive patients may not present as typical
SSc and detecting anti-RNAP III may have predictive value.
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Introduction
Specific autoantibodies in systemic rheumatic diseases
are useful biomarkers associated with certain diagnoses
and/or clinical manifestations [1]. Several autoantibo-
dies, including anti-topoisomerase I (topo I), -centro-
mere (ACA), -RNA polymerase III (RNAP III), -U3RNP/
fibrillarin, and -Th/To, have been reported to be asso-
ciated with scleroderma (systemic sclerosis, SSc); some
are considered highly specific disease markers while
others are considered relatively specific [2]. Anti-RNAP
III that is considered highly specific for SSc, is a rela-
tively new disease marker of SSc; however, it has
become a popular test in the last several years thanks to
the wide availability of commercial ELISA kits [1,2].
Detecting anti-RNAP III in some undiagnosed patients
would not be totally unexpected, considering that auto-
antibodies are usually produced prior to typical clinical
manifestations [3]. However, detection of anti-RNAP III
in non-SSc patients or prior to clinical SSc has rarely
been reported [4]. Although anti-RNAP III antibodies
are associated with rapid progression of the disease and
the interval between the onset of Raynaud’s phenom-
enon (RP) and SSc is short [2,5], the time course of the
onset of RP and SSc has not been well described. In the
present study, the clinical features of anti-RNAP III
positive patients in a cohort of an unselected population
in a rheumatology clinic that includes undiagnosed
patients and patients with a wide variety of diagnosis,
were characterized. The relationships among detection
of anti-RNAP III antibodies, onset of RP, and develop-
ment of sclerodermatous skin changes, were also sys-
tematically analyzed.
Materials and methods
Patients
All 1,966 subjects enrolled in the University of Florida
Center for Autoimmune Diseases (UFCAD) registry
from 2000 to 2010 were studied. Diagnoses of the
patients include 434 SLE, 119 SSc, 85 polymyositis/der-
matomyositis, and various other diagnoses, and many
remained undiagnosed for a specific systemic autoim-
mune disease. At each visit of the enrolled subjects, a
form with a standard check list of symptoms and physi-
cal findings, including Raynaud’s phenomenon and
sclerodermatous skin changes, was filled out by physi-
cians in addition to an entry in the medical chart. The
data from the form were then entered into a computer
database. Clinical information for the study was from
the database and chart records. Raynaud’s phenomenon
was defined as sudden reversible white pallor of acral
structures, which typically is followed by color changes
to purple then to red [6]. The protocol was approved by
the Institutional Review Board (IRB). This study meets
and is in compliance with all ethical standards in
medicine. Informed consent, including the publication
of the study, was obtained from all patients according to
the Declaration of Helsinki.
Immunoprecipitation
Autoantibodies in sera from the initial visit of each
patient were screened by immunoprecipitation (IP)
using 35S-methionine labeled K562 cell extract. Anti-
RNAP III were determined using reference sera [4]. Spe-
cificity of autoantibodies was determined using pre-
viously described reference sera [7].
Immunofluorescent antinuclear antibodies
Immunofluorescent antinuclear/cytoplasmic antibodies
(HEp-2 ANA slides; INOVA Diagnostics, San Diego,
CA, USA) were tested using a 1:80-diluted human
serum and DyLight488 donkey IgG F(ab’)2 anti-human
IgG (gamma-chain specific, 1:200 dilution; Jackson
ImmunoResearch Laboratories, Inc., West Grove, PA,
USA) [8].
ELISA
Sera were tested for IgG anti-RNAP III antibodies using
a commercial ELISA kit (QUANTA Lite® RNA Pol III,
INOVA Diagnostics) following the manufacturer’s
instruction.
Statistical analysis
Data between groups were compared by the Mann-
Whitney test using Prism 5.0 for Macintosh (GraphPad
Software, Inc., San Diego, CA, USA). P < 0.05 was con-
sidered significant.
Results
Autoantibodies to RNA polymerase I/III were found in
21 patients (1.1% of 1,966); 18 Caucasians, 2 African
Americans, and 1 of mixed ethnic background. Sixteen
of 21 cases had a diagnosis of SSc at the initial visit
while 5 did not (Table 1). In the Caucasian patients, 14
out of 18 were diagnosed as having SSc at the initial
visit. Four patients (cases 1, 3, 4, 5) did not fulfill the
SSc criteria at the initial visit when serum anti-RNAP I/
III antibodies were detected. Two African American
patients had a diagnosis of SSc at the initial visit. A
patient of mixed ethnic background did not meet the
American College of Rheumatology (ACR) criteria at
the initial visit (case 2). Patients who did not meet SSc
criteria at the initial evaluation are summarized below
and in Table 1. A brief history of an additional case 6,
in which sclerodermatous change was followed by RP
two years later, is also described.
Case 1: A fifty-year-old female was hospitalized for
shortness of breath and chest pain in March 2000.
Numbness in her left second digit also developed and
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became progressively ischemic and painful, resulting in
amputation due to gangrene in April of that year. A
hypercoagulable state secondary to malignancy was sus-
pected, but nothing was found. In May 2000, she devel-
oped ischemic areas on the tips of the fingers and toes,
and was put on anticoagulation therapy. Her ANA
(speckled pattern, titer 1:640) and anti-RNAP I/III anti-
bodies were positive but no scleroderma or RP was
noted. Prednisolone (40 mg/day) was started and her
condition was followed at her local clinic. She developed
proximal scleroderma and scleroderma renal crisis in
March 2001.
Case 2: A 39-year-old female developed polyarthritis
involving the metacarpophalangeal joints (MCPs), proxi-
mal interphalangeal joints (PIPs), wrists and ankles in
August 2004. The initial diagnosis was early synovitis
without evidence of systemic rheumatic disease. Rheu-
matoid factor (RF) and anti-CCP were negative but
ANA (speckled pattern, titer 1:160) and anti-RNAP I/III
antibodies were positive. She developed sclerodermatous
changes in her fingers, forearms and face in October
2004, which rapidly progressed to proximal scleroderma
in November. Monthly i.v cyclophosphamide therapy
was started, followed by prednisolone (50 mg/day) in
December. She started having RP in February 2005 and
verapamil and bosentan were started. Right heart cathe-
terization in March 2005 suggested mild pulmonary
hypertension (PH). Scleroderma progressed to involve
the chest, shoulders and abdomen, and flexion contrac-
tures of the fingers were noted in March 2005. She was
hospitalized in 2008 for anemia caused by gastric antral
vascular ectasia (GAVE).
Another very similar case was seen. A 32-year-old
Caucasian female was classified as having early synovitis
(wrists, MCP, PIP joints) with a positive ANA (speckled
and nucleolar pattern). A year later she developed proxi-
mal scleroderma and visited the UFCAD. RP developed
six months later.
Case 3: A 57-year-old female, who had a 10-year his-
tory of RP, visited a clinic for worsening RP in April
2002, when hydroxychroloquine was started. In May
2002 she was hospitalized elsewhere for dyspnea,
hypoxia and a nonproductive cough. Pleural effusions
and heart failure were found, and her cardiac ejection
fraction was 25%. A diagnosis of dilated cardiomyopathy
was made. She also developed hypertension and renal
dysfunction. Prednisolone (60 mg/day) and azathioprine
were started but the latter was discontinued due to a
rash. In July 2002, she developed renal failure and
hemodialysis was started. Her kidney biopsy revealed
thrombotic microangiopathy. Decreased sensation of her
lower left leg was diagnosed as neuropathy. She visited
UFCAD in July 2002. No sclerodactyly was noted but
one teleangiectasia was found in the digit. ANA
(speckled and nucleolar pattern, titer 1:80) and anti-
RNAP I/III were positive.
Case 4: A 67-year-old female who was followed by a
pulmonologist for a three-year history of respiratory
symptoms was referred to the UFCAD for a positive
ANA (speckled and nucleolar) and ILD. Anti-RNAP I/
III antibodies were positive. She did not have rheumato-
logical symptoms, including arthritis, sclerodermatous
changes, or RP at the one-year follow-up.
Case 5: A 68-year-old female was followed for Sjög-
ren’s syndrome. She had dry eyes, a dry mouth and a
positive salivary gland biopsy but no sclerodermatous
skin changes, RP or ILD. She was also positive for ACA
by immunofluorescence (Figure 1B panel 5)
Table 1 Five anti-RNAP III positive cases that were not classified as SSc at their initial visit
1 2 3 4 5
Initial f/u Initial f/u
Diagnosis Vasculitis? SSc Poly
-arthritis
SSc Sine SSc? ILD Sjögren’s syndrome
Race/gender WF Mixed F WF WF WF
Anti-RNAP III
ELISA (u)
16 NA 99 127 8 15
to 47
42
Proximal scleroderma N Y
< 10 mo
N Y
3 mo
N N N
Sclerodactyly N Y
< 10 mo
N Y
2 mo
N N N
Pitting scar N N N N N N N
ILD N N N N N Y N
Raynaud’s phenomenon N ? N Y
6 mo
Y
For 10 y
N N
Other Renal crisis
10 mo
Flex.cont
PH
ARF (TMA), DCM
ARF, acute renal failure; DCM, dilated cardiomyopathy; W, white; F, female; Flex cont, flexion contracture; f/u, follow up; ILD, interstitial lung disease; N, no; NA,
not available; PH, pulmonary hypertension; SSc, systemic sclerosis, scleroderma; TMA, thrombotic microangiopathy; Y, yes
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Figure 1 Anti-RNAP III antibodies by immunoprecipitation, immunofluorescence, and ELISA. A). Immunoprecipitation using 35S-
methionine labeled K562 cell extract. 35S-methionine labeled K562 cell extract was immunoprecipitated by serum samples from patients with
anti-RNA polymerase I/III, who had atypical clinical presentations (Table 1) and controls. RNAPs, RNA polymerases; I, II, III, two largest subunits of
RNA polymerase I, II, and III, respectively; lane I, II, III, a reference serum with anti-RNAP I/II/III; lane I, III, a reference serum with anti-RNAP I/III; 1 to
6, IP with sera from cases 1 to 6; NHS, normal human serum; positions of molecular weight markers are also indicated. B). Immunofluorescence.
HEp-2 ANA slide was stained with sera from cases 1 to 6 (Table 1) at 1:80 dilutions. C). Anti-RNAP III levels by ELISA. Sera from 21 cases with
anti-RNAP I/III were tested by ELISA. Six cases of atypical presentation (Table 1) and 15 cases of typical presentation of SSc are shown. P = 0.04
by Mann-Whitney; closed circle, SSc; open circles, atypical cases in Table 1. D). Anti-RNAP III levels over time. Sera from cases 2, 4 and 6 over
time were tested by anti-RNAP III ELISA. Time points of onset of sclerodermatous skin change (black arrowhead) or Raynaud’s phenomenon
(white arrowhead) are indicated. A cut-off (20 units) is shown as shaded area.
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Case 6, (not included in Table 1 since she had a diag-
nosis of SSc at the initial visit), was a 61-year-old Cau-
casian female who developed tingling fingertips; carpal
tunnel syndrome was suspected. The tingling was fol-
lowed by swelling and pain in her hands and scleroder-
matous skin changes to her forearm. She visited
UFCAD and had a diagnosis of diffuse SSc. RP devel-
oped two years later.
Two patients (cases 1 and 2), who had anti-RNAP III
without SSc but later developed SSc, three patients who
did not meet the SSc criteria during observation (cases
3 to 5), and a patient who had SSc without RP and
developed RP two years later (case 6), were classified as
“atypical presentation” cases. Anti-RNAP III antibodies
in these 6 cases were compared with 15 cases of “typical
presentation” in which patients had SSc with RP when
they visited clinic and serum samples were collected.
Sera from all six cases of “atypical presentation”
clearly immunoprecipitated RNAP I and III (Figure 1A).
The intensity of RNAP I and III were similar in two
patients who developed SSc later (cases 1and 2, lanes 1
and 2 in Figure 1A) and a patient with SSc who devel-
oped RP two years after the development of SSc (case 6,
lane 6). In contrast, RNAP I was predominant with
much weaker RNAP III in three patients, (cases 3 to 5,
lanes 3 to 5 in Figure 1A), who did not have a diagnosis
of SSc. RNAP III and II are known to distribute in the
nuclei while RNAP I localizes to the nucleoli [9,10].
Consistent with their localization patterns, sera from
cases 3 to 5 (panels 3 to 5 in Figure 1B) that had predo-
minant RNAP I IP, had dominant nucleolar staining
compared with their nuclear staining. Case 5 had ACA
in addition (Figure 1B panel 5).
Levels of anti-RNAP III were tested by ELISA com-
paring cases with atypical presentation vs typical presen-
tation of SSc (Figure 1C). Levels of anti-RNAP III in the
former group were lower than those in the latter (P =
0.04 by Mann-Whitney test). Also, anti-RNAP III ELISA
negative (< 20 units) was common in the former (3 of
6) vs the latter group (1 of 15, P = 0.0526 by the Fisher’s
exact test). Specifically, 2 of the ELISA negative patients
were cases 3 and 4 who had week bands by IP and did
not develop scleroderma. Thus, although all cases
immunoprecipitated RNAP III, levels of anti-RNAP III
by ELISA were lower in cases with atypical clinical pre-
sentations compared with those in typical SSc.
Sequential sera from cases 2, 4, and 6 were available
for testing by anti-RNAP III ELISA. In case 2, levels of
anti-RNAP III were high (99 units) at the initial visit
despite complete lack of scleroderma or RP, indicating
that anti-RNAP III can be produced prior to clinical
manifestations similar to other disease marker autoanti-
bodies. Levels of anti-RNAP III went up when the
patient developed sclerodermatous skin changes
followed by RP. In case 4, anti-RNAP III became posi-
tive while the patient was followed up for ILD, but no
clinical changes were observed. In case 6, the patient
had low levels of anti-RNAP III when she visited
UFCAD with diffuse SSc but without RP. Her anti-
RNAP III levels increased from 33 units to 107 units to
112 units prior to the development of RP two years
later.
RP is often the first symptom of SSc and may start
many years prior to development of SSc [2]. Since cases
of anti-RNAP III positive patients who developed sclero-
dermatous changes prior to RP were noted, the
sequence of RP and sclerodermatous changes were
reviewed carefully, comparing SSc patients with anti-
RNAP III vs other specificities in the UFCAD cohort
(Table 2 cases 3 to 5 are not included). Almost all of
the SSc patients had RP during the course of the disease
regardless of the autoantibody specificity. However, only
3 of 17 anti-RNAP III positive patients did not have RP
by the time of initial visit (P = 0.07 vs topo I group, P =
0.01 vs all others combined). When the medical history
was carefully reviewed, sclerodermatous changes
appeared prior to RP in 31% (5 of 16) of anti-RNAP III
patients while this occurred only in one anti-topo I posi-
tive patient in other groups (RNAP III vs topo I, P =
0.03; RNAP III vs ACA, P = 0.04; RNAP III vs others, P
= 0.002). The development of RP and sclerodactyly were
separated by more than one year only in 25% of anti-
RNAP III patients vs 50 to 58% of individuals with
other specificities (P = 0.08 vs all others). The time
between RP and the development of scleroderma was
shorter in anti-RNAP III vs ACA group or all others
combined (P = 0.03 by Mann-Whitney).
Discussion
Anti-RNAP III antibodies are considered highly speci-
fic for the diagnosis of SSc. Among five patients who
did not meet the SSc criteria at the initial visit, two
developed SSc during follow-up; however, three did
not (Table 1). Case 3 had RP and an episode consistent
with scleroderma renal crisis and Ccase 4 had ILD.
Although their SSc-like features involving internal
organs are limited compared with reported cases
[11,12], it seems reasonable to suspect that they had a
pathogenetic condition similar to systemic sclerosis
sine scleroderma, in particular with detection of anti-
RNAP III. Similar cases of scleroderma renal crisis
with minimal or no features of SSc, some with anti-
RNAP III antibodies, have been reported [13,14].
Although we should not classify all ANA-positive
acute renal failure or ILD as systemic sclerosis sine
scleroderma, identifying SSc-specific autoantibodies
may prove useful in understanding the pathogenetic
mechanism and selecting treatment options.
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Detection of anti-RNAP III by ELISA in patients with
diagnosis other than SSc was occasionally reported, but
most of them were interpreted as false positives based
on negative results by IP [15,16]. The presence of anti-
RNAP III confirmed by IP in non-SSc patients, as
shown in the present study, was rarely reported [4,15].
Several studies compared ELISA and IP to estimate spe-
cificity and sensitivity of ELISA. IP positive ELISA nega-
tive (false negative) is reported in 4 to 9% [15-17], while
IP negative ELISA positive (false positive) is 12 to 15%
[15,16]. Although confirmation of IP negative appears to
be incomplete, other study suggests that false positive
by ELISA is as low as ~2% [17]. False positives appear
to be more common among weakly positive samples or
in non-SSc patients [15,16]. Our data showed that 19%
(4 of 21, 1 later became positive) of IP positives were
ELISA negative (Figure 1). Anti-RNAP III ELISA has
been shown to have a good sensitivity and specificity
[15-17] and has made the testing for this common SSc
antibody widely available. Thus, it significantly helps
clinical practice since IP is not available to most clini-
cians. Nevertheless, it should be kept in mind that there
are false positives and false negatives in ELISA. In parti-
cular, cautious interpretation will be necessary for
weakly positive samples or positives among non-SSc
patients. IP should remain the gold standard for anti-
RNAP III antibody testing.
It is of interest that all three cases of non-SSc anti-
RNAP III positive patients had predominant RNAP I
reactivity with weak RNAP III reactivity and had a
strong nucleolar staining that is not always seen in anti-
RNAP I/III positive SSc patients [17,18]. In addition,
anti-RNAP III levels increased prior to development of
scleroderma or RP in cases 2 and 6, suggesting a corre-
lation between levels of anti-RNAP III and disease activ-
ity. One study suggested a link between increasing levels
of anti-RNAP III after the initial visit and increasing
total skin score and onset of renal crisis over time [15].
Another study reported an association of anti-RNAP III
levels and skin score and a negative correlation with a
pulmonary function test [19]. These are consistent with
the present cases; however, the course of anti-RNAP III
during the onset of sclerodermatous skin changes or RP
has not been reported previously.
A unique feature observed in anti-RNAP III positive
SSc patients was the late development of RP, which
has also been suggested [2], but details were not
reported. Even if RP appears prior to scleroderma, the
interval is often within a year, consistent with the pre-
viously reported rapidly progressive nature of SSc in
anti-RNAP III positive patients [2,20]. The develop-
ment of RP after the initial visit was observed in only
three cases with anti-RNAP III but did not appear in
other groups at all, and 31% (5 of 16) in the anti-
RNAP III group had scleroderma prior to RP. In con-
trast, RP preceded scleroderma in most cases of SSc
[2]. Sclerodermatous skin without RP is considered
characteristic of malignancy-associated pseudoscler-
oderma [21-23]. However, anti-RNAP III positive SSc
should be considered in the differential diagnosis of
scleroderma without RP, since 31% of our anti-RNAP
III positive SSc developed sclerodermatous changes
prior to RP.
Conclusions
In summary, anti-RNAP III is highly specific for SSc and
related conditions even in an unselected population
from a rheumatology clinic. In cases with atypical SSc,
dominance of anti-RNAP I and strong nucleolar staining
may be seen. The unusual presentation of the occur-
rence of scleroderma without RP appears to be charac-
teristic of anti-RNAP III positive SSc. In some cases,
internal organ involvement, such as renal or lung dis-
ease, may precede skin manifestation of SSc, and detec-
tion of anti-RNAP III provides useful diagnostic and
prognostic information.
Table 2 Raynaud’s phenomenon and autoantibodies in scleroderma patients
RNAP III
(n = 18)
Topo I
(n = 24)
ACA
(n = 15)
U3RNP
(n = 9)
Th/To
(n = 8)
Prevalence of RP 94% (16/17) 96% (23/24) 100% (15/15) 100% (9/9) 87% (7/8)
Absence of RP at first visit
(in RP positive cases)
18% (3/16)1, 2 0% (0/23)2 0% (0/15) 0% (0/9) 0% (0/7)
Scleroderma prior to RP 31% (5/16)3, 4, 5 4% (1/23)3 0% (0/15)4 0% (0/9) 0% (0/8)
RP to scleroderma > 1 y 25% (4/16) 6 53% (10/19) 58% (7/12) 50% (4/8) 57% (4/7)
RP to scleroderma
(year, mean ± SD)
1.5 ± 5.37, 8
(0.2 ± 1.2)9
4.1 ± 8.9 5.7 ± 5.87 1.1 ± 1.7 2.6 ± 3.4
RP, Raynaud’s phenomenon
1 RNAP III vs others, P = 0.01; 2 RNAP III vs Topo I, P = 0.07; 3 RNAP III vs Topo I, P = 0.03; 4 RNAP III vs ACA, P = 0.04; 5 RNAP III vs others, P = 0.002; 6 RNAP III vs
others, P = 0.08; 7 RNAP III vs ACA, P = 0.03; 8 RNAP III vs others, P = 0.03; 9 Value after excluding an outlier that has 21 years interval between RP to
scleroderma.
1-6 by Fisher’s exact test, 7,8 by Mann-Whitney
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